Remove

Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		09890177				
	Filing Date		1998-10-05				
First Named Inventor Warre		Warre	en P. Williamson IV et al.				
	Art Unit		3736				
	Examiner Name	Charl	es Alan Marmor II				
	Attorney Docket Number		BIOP-02				

				0.3.	PATENTS	Remove				
		Kind Code ¹	Issue Date Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Releva Figures Appear				
	1	6387653	B1	2002-05-14	-14 Voneiff et al.					
	2	5928934		1999-07-27	McCormick					
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.		Add		
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	iner Cite No Publication Number Kind Code Date Name of Patentee or Application of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear						
			_				_			
	1									
If you wis	Ĺ	dd additional U.S. Pubi					d buttor	$\overline{}$		
If you wis	Ĺ	dd additional U.S. Pub		plication citatio			d buttor	Add Remove		
If you wisi Examiner Initial*	h to a	dd additional U.S. Pub Foreign Document Number ³		FOREIGN PAT			e or	Remove Pages,Coli where Rele	or Relevant	Ts
Examiner	h to a	Foreign Document	Country	FOREIGN PAT	Publication	Name of Patente Applicant of cited	e or	Remove Pages,Coli where Rele Passages	evant or Relevant	Ts

II C DATENTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Examine

Application Number		09890177			
Filing Date		1998-10-05			
First Named Inventor Warre		en P. Williamson IV et al.			
Art Unit		3736			
Examiner Name Char		es Alan Marmor II			
Attorney Docket Numb	er	BIOP-02			

If you wisl	If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
	NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	Cite No	(bool	lude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item ok, magazine, journal, sorfal, symposium, catalog, etc), date, pages(s), volume-issue number(s), lisher, city and/or country where published.						
EUROPEAN PATENT OFFICE, Supplementary European Search Report in corresponding EP 02776027, July 7, 2006									
If you wisl	If you wish to add additional non-patent literature document citation information please click the Add button Add								
	EXAMINER SIGNATURE								
Examiner Signature Date Considered									

1 See Kint Codes of USPTO Petert Documents at invent/ISPTO_COV or MFEP 961.04. * Enter office that issued the document, by the No-teller Code (WIPO-Standard ST3.) ** The planeses peter for counters, the includation of the parent or the enter process the serial number of the patient or heavy or the Emperor number process the serial number of the patient content. * In the Counter of the Peter or number of the patient Code (WIPO-Standard ST.16 if possible. * Applicant is to place a check mark here if English tanguage threatistics in a state-due.**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09890177		
Filing Date		1998-10-05		
First Named Inventor Warre		en P. Williamson IV et al.		
Art Unit		3736		
Examiner Name Char		ies Alan Marmor II		
Attorney Docket Number		BIOP-02		

36330

CERTIFICATION STATEMENT

Please see	37	CFR .	1 97	and	1 02	to	make t	ha	annror	rioto	cal	lanti	nn/	۱۵	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CPR1 156(c) more than there morther poor to the filing of the information disclosure that the contract of the contract

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Kevin G. Rooney

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature

Registration Number

Torri or the signature.							
Signature	/Kevin G. Rooney/	Date (YYYY-MM-DD)	2006-09-05				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operament of Commence, P. 0. 80x 1450, Alexandri, V.3. 2313-1450, D. ON TO SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, VA.22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the contraction of the contraction of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record vals filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to public insepections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.